Dr. Augusto Miravalle and Kathy Keefer of Brain Health Center of the Rockies Join Nira Medical as key advisors

August 8, 2025
Published
Nira Medical Editorial
Author

We are thrilled to welcome Dr. Augusto Miravalle, Chief of Neuroimmunology and Multiple Sclerosis at Rush University, and Kathy Keefer, President of the Brain Health Center of the Rockies, to the Nira Medical team.

Dr. Miravalle will serve as Medical Director of Education, and Kathy will join as Manager of Patient Education at Nira Medical.

A nationally recognized leader in neuroimmunology, Dr. Miravalle has devoted his career to advancing care, research, and education in multiple sclerosis. He has held key leadership roles at top academic institutions and is widely published in MS and CNS inflammatory disorders. His work is defined by a deep commitment to clinical excellence and mentorship of the next generation of MS specialists.

Kathy Keefer brings decades of experience in patient advocacy, education, and brain health programming. As President of the Brain Health Center of the Rockies, she has helped thousands of patients navigate the complexities of MS through education, emotional support, and community engagement. Her work is grounded in empathy, accessibility, and empowering patients to take an active role in their care.

In partnership with Dr. Mike Edgeworth, Nira’s Chief Medical Officer, they will lead the development of a comprehensive suite of programs designed to advance clinical education, peer collaboration, and patient empowerment across the Nira Medical network.

“We couldn’t be more excited to have Dr. Miravalle and Kathy Keefer join Nira Medical,” said Dr. Mike Edgeworth, Chief Medical Officer. “Their passion for advancing brain health and their deep expertise in both clinician and patient education make them uniquely suited to help lead this next chapter of growth. Together, we’re building something truly special for the MS and neurology community.”

“I’m honored to join Nira Medical at such a pivotal time,” said Dr. Miravalle. “There is a clear vision here to elevate the standard of care in neuroimmunology by investing in education, collaboration, and patient connection. I look forward to helping shape programs that support both clinicians and the people they serve.”

These efforts reflect Nira Medical’s commitment to building a national model for brain health that is grounded in clinical excellence, patient-centered care, and continuous learning.

Stay tuned for more updates in the months ahead.

More to read

September 11, 2026
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
The FDA approval of ISEMBYLD™ brings a new treatment option to the SMA community. At CTNC, Dr. Adam Horvit and our team care for six patients receiving apitegromab through an Expanded Access Program.
Clinical Excellence
Real-world Evidence
Learn More
September 25, 2025
Nira Medical at ECTRIMS 2025
At ECTRIMS 2025, Dr. John Foley joined experts from around the world to explore how AI-powered analysis of real-world clinical data can provide new insights into drug efficacy, safety, and outcomes in multiple sclerosis. He was joined at the meeting by many neurologists and APPs from across the Nira Medical network, who participated in research presentations, discussions, and the broader exchange of ideas in MS care.
Research
Learn More
May 6, 2026
Nira Medical at American Academy of Neurology 2026 Annual Meeting
Nira Medical was proud to be part of AAN 2026 through research presentations and panel discussions spanning community-based research, patient experience, and expanding brain health beyond the clinic.
Clinical Excellence
Research
Learn More